Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.

Gastric cancer (GC) is the fourth most common type of cancer, accounting for an estimated one million new cases annually worldwide. Locally advanced GC often recurs, even following curative surgical resection. Therefore, there is a need for an effective adjuvant chemotherapy regimen. The aim of this trial was to investigate the maximum tolerated dose (MTD) of S-1 when administered in combination with oxaliplatin in postoperative GC patients. Oxaliplatin was administered at a fixed dose of 130 mg/m2 on day 1. S-1 was administered from day 1 to 14 of a 3-week cycle and escalated by 10 mg/m2/day from 60 to 80 mg/m2/day. A total of 15 patients were enrolled in this study. No dose-limiting toxicities (DLTs) occurred at level 1 (S-1, 60 mg/m2; n=3). One case of DLT (grade 3 vomiting) occurred at level 2 (S-1, 70 mg/m2; n= 6), whereas 2 cases of grade 3 vomiting were observed at level 3 (S-1, 80 mg/m2; n=6). Based on these results, the MTD of S-1 was initially determined to be 70 mg/m2. Furthermore, we observed that cytochrome P450 2A6 (CYP2A6) 41349640C>G was associated with severe neutropenia (C/C vs. C/G vs. G/G = 0 vs. 33.33 vs. 100%; P=0.03297, Fisher's exact test) during the entire course of the treatment.

[1]  T. Kamataki,et al.  A novel single nucleotide polymorphism altering stability and activity of CYP2a6. , 2001, Biochemical and biophysical research communications.

[2]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[3]  J. Ying,et al.  S-1 combined with oxaliplatin as first line chemotherapy for Chinese advanced gastric cancer patients. , 2012, Hepato-gastroenterology.

[4]  Xiao-dong Zhu,et al.  Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer , 2008, Anti-cancer drugs.

[5]  Lin Feng.  Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer , 2008 .

[6]  I. Choi,et al.  CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients , 2011, British Journal of Cancer.

[7]  T. Glisovic,et al.  Heterogeneous nuclear ribonucleoprotein A1 and regulation of the xenobiotic-inducible gene Cyp2a5. , 2002, Molecular pharmacology.

[8]  M. Kurihara,et al.  Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer , 2000, Oncology.

[9]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[10]  W. Budach,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[11]  K. Hirakawa,et al.  Alternative pharmacokinetics of S‐1 components, 5‐fluorouracil, dihydrofluorouracil and α‐fluoro‐β‐alanine after oral administration of S‐1 following total gastrectomy , 2007 .

[12]  Kyle Christian,et al.  Interaction of heterogeneous nuclear ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications for post-transcriptional regulation of the CYP2A6 gene. , 2004, Molecular pharmacology.

[13]  Y. Kodera,et al.  A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  Inkyung Jung,et al.  A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. , 2012, European journal of cancer.

[15]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Glisovic,et al.  Heterogeneous Nuclear Ribonucleoprotein A 1 and Regulation of the Xenobiotic-Inducible Gene Cyp 2 a 5 , 2002 .

[17]  T. Yoshikawa,et al.  A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  M. Nakajima,et al.  Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. , 2002, British journal of clinical pharmacology.

[19]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[20]  M. Kurihara,et al.  Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. , 2000, Oncology.

[21]  J. Shin,et al.  Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity , 2011, British Journal of Cancer.

[22]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[23]  K. Hirakawa,et al.  Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy. , 2007, Cancer science.

[24]  Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer , 2008, British Journal of Cancer.

[25]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[26]  Jeffrey P. Jones,et al.  An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. , 2002, Biochemical and biophysical research communications.

[27]  Kazuhiro Araki,et al.  CYP2A6 and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1 , 2008, Cancer science.

[28]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[29]  J. Wanders,et al.  Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). , 2003, European journal of cancer.

[30]  Sung Sook Lee,et al.  Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer , 2010, Cancer Chemotherapy and Pharmacology.

[31]  T. Takayama,et al.  Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients , 2007, Cancer Chemotherapy and Pharmacology.

[32]  I. Choi,et al.  Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. , 2009, Pharmacogenomics.

[33]  Y. Ohashi,et al.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  K. Sugimachi,et al.  Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. , 1998, European journal of cancer.

[35]  K Chiba,et al.  Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  D. Cunningham,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2010, The New England journal of medicine.

[37]  H. Imamura,et al.  Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced gastric cancer. , 2013 .

[38]  W. Sadee,et al.  Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway. , 1982, Biochemical pharmacology.